REMEGEN CO., LTD.

Business Segments RemeGen Co., Ltd.

Stocks

9995

CNE1000048G6

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:08 18/06/2026 pm IST			5-day change	1st Jan Change
68.50 ^HKD	+1.63%		-1.65%	-4.86%

08/06	Remegen Co., Ltd. Receives Nmpa Approval for New Indication of Telitacicept for Injection for Treatment of Sjögren?S Syndrome	CI
08/06	Remegen Co., Ltd. Receives Conditional Approval for Marketing of Telitacicept Injection for Treatment of Iga Nephropathy	CI

Sales 2025 by Business Segment

© MarketScreener.com See more

Sales 2025 by Geography

© MarketScreener.com See more

Historical Breakdown of Revenue by Business Segments

Net Income: Breakdown by Business Segment

Breakdown by Business Segment (CNY)

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Biological Products
Biopharmaceutical Research,Service,Production and Sales				142.39Cr	77Cr	108.3Cr	171.69Cr	325.11Cr
Total Assets				415.92Cr	602.12Cr	552.82Cr	549.85Cr	724.81Cr
Interest Expense				-53.23L	-67.57L	-2.31Cr	-7.24Cr	-7.02Cr
Income Tax Expense				-	-	-	-	7L
CAPEX				-62Cr	-76Cr	-85Cr	-27Cr	-20Cr
EBT				28Cr	-100Cr	-151.12Cr	-146.84Cr	71Cr
Gross Profit				135.67Cr	50Cr	-	-	-
D&A				12Cr	18Cr	23Cr	29Cr	31Cr
Operating Income				-	-	-150.15Cr	-145.57Cr	72Cr
Net Income				28Cr	-100Cr	-151.12Cr	-146.84Cr	71Cr

Geographical Revenue Distribution History

Geographical breakdown of sales (CNY)

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Mainland China				13Cr	72Cr	105.43Cr	170.42Cr	227.64Cr
Total Assets				178.11Cr	266.09Cr	-	308.83Cr	311.61Cr
USA				129.26Cr	4.44Cr	2.87Cr	1.27Cr	97Cr
Total Assets				6.55Cr	6.49Cr	-	4.32Cr	2.51Cr
Total Assets				66T	-	-	-	-

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!